Instructions Specific to This Exam

1. This examination contains one question worth a total of 100 marks.

2. You will be assessed primarily on your knowledge of the relevant constitutional provisions, cases and assigned materials identified in the Canadian Constitutional Law syllabus, together with your ability to recognize the constitutional issues raised by the facts and analyze the competing arguments relevant to those issues.

3. No marks are awarded for merely reproducing or summarizing the facts. You are expected to identify the relevant constitutional issues, state the governing legal rules and apply those rules closely to the facts.

4. Do not provide a general essay on Canadian constitutional law or work through a memorized checklist of constitutional doctrines that are not reasonably raised by the facts.

5. Full citations are not required for cases contained in the assigned materials. However, where an assigned authority is relevant, identify it with sufficient precision to demonstrate knowledge of the governing law.

6. You are asked to prepare a memorandum of law. You do not need to spend examination time creating formal headings such as “To,” “From,” “Date” or “Re.”

7. In addressing the division of powers, distinguish carefully between:

   • the pith and substance of the challenged legislation;

   • whether the legislation falls within a valid federal or provincial head of power;

   • the effect of incidental intrusion into the other level of government’s jurisdiction;

   • the possible application of the ancillary powers doctrine; and

   • the separate question of federal paramountcy where valid federal and provincial laws overlap.

8. Where a Charter right is engaged, identify the right or freedom, analyze whether it has been infringed, consider whether the infringement can be justified under s. 1, and address the appropriate remedy.

9. Do not assume that a finding of federal paramountcy renders provincial legislation invalid. Distinguish validity from operability.

10. Where different provisions of a legislative scheme raise different constitutional issues, analyze them separately rather than assuming that the constitutionality of one provision determines the validity of the entire statute.

11. Do not address Aboriginal or treaty rights, constitutional amendment procedures, or s. 33 of the Charter.

12. Write a clear and organized answer in complete sentences.

QUESTION

FACTS

NeuroVanta Health Inc. (“NeuroVanta”) is an Ontario corporation that designs and manufactures medical devices using targeted electrical stimulation of the brain.

Its principal product is the PulseArc, a headset that delivers precisely calibrated electrical impulses to areas of the brain associated with mood regulation.

PulseArc is intended for use under the supervision of a physician or other specially trained health professional.

It is not sold directly to consumers.

Approximately 80% of NeuroVanta’s sales are to clinics in Ontario. The remaining 20% are to clinics in British Columbia, Alberta and Nova Scotia.

The technology has attracted considerable attention as a possible treatment for severe depression in patients who have not responded to conventional therapies.

Between 2023 and 2025, several other companies began selling more powerful neurostimulation devices directly to consumers through websites and social-media advertisements.

Those devices could be ordered online and used at home without medical supervision.

During that period, Canadian hospitals reported 14 serious neurological incidents associated with unsupervised home use of consumer neurostimulation devices.

Several patients experienced seizures.

Others suffered prolonged disorientation or loss of consciousness.

None of the reported serious incidents involved PulseArc or another device being used in a licensed medical clinic under professional supervision.

Provincial regulation varied considerably.

Some provinces regulated neurostimulation clinics as health facilities.

Others regulated the professionals operating the devices but did not separately regulate the devices themselves.

Two provinces had no legislation specifically directed at neurostimulation.

In 2025, Parliament conducted hearings concerning the emerging industry.

The federal Minister of Health told a parliamentary committee:

“These products increasingly move through a national online market. A device can be advertised in one province, purchased from another and delivered anywhere in Canada within days. Canadians should not face fundamentally different safety standards depending on where they live.”

Several witnesses urged Parliament to distinguish between unsupervised consumer devices and professionally supervised clinical treatment.

A medical association submitted evidence that:

“The existing record discloses materially different risk profiles between unsupervised consumer use and physician-supervised clinical use.”

A proposed amendment would have exempted neurostimulation used exclusively in provincially licensed medical facilities.

The amendment was defeated.

The Minister explained:

“A device that presents neurological risk does not cease to present risk because it is located inside a clinic. A national system should assess the device itself.”

Parliament subsequently enacted the fictional National Neurotechnology Safety Act (“NNSA”).

The preamble states that Parliament is concerned about:

“serious risks to neurological health associated with inadequately tested neurostimulation technologies and the need for consistent minimum standards concerning such technologies throughout Canada.”

The material provisions state:

2. “High-intensity neurostimulation device” means any device intended to alter neurological, cognitive or emotional functioning through electrical or magnetic stimulation above a prescribed intensity.

4(1). No person shall manufacture, import, sell, lease or provide treatment using a high-intensity neurostimulation device unless the device is listed on the National Neurotechnology Registry.

4(2). Subsection (1) applies whether the activity takes place interprovincially or wholly within one province.

5(1). The Minister may list a device where satisfied, on the basis of scientific evidence, that the device is sufficiently safe and therapeutically effective for the proposed use.

7(1). No person shall advertise, promote or otherwise communicate for the purpose of encouraging the therapeutic use of an unlisted high-intensity neurostimulation device.

7(2). No person shall make a therapeutic claim concerning a listed device unless the claim appears in substantially identical form in the federally approved product monograph.

9(1). A person who suffers physical, psychological or economic loss as a result of conduct contrary to s. 4 or s. 7 may bring a civil action against the person responsible for the contravention.

9(2). Liability under subsection (1) does not depend upon proof of negligence.

11. A person who knowingly contravenes s. 4 or s. 7 is guilty of an offence punishable on indictment by a fine or imprisonment for a term not exceeding two years, or both.

The Act establishes a specialized federal regulatory office to maintain the Registry, evaluate scientific evidence and monitor compliance nationally.

Federal officials may conduct inspections and order the removal of unlawfully marketed devices from commerce.

The Minister described s. 9 as:

“an additional deterrent that ensures those who profit from violating national neurotechnology standards bear the losses caused by their conduct.”

Before the federal statute was enacted, Ontario had adopted the fictional Therapeutic Neurostimulation Clinics Act (“TNCA”).

The TNCA establishes a provincial licensing system for clinics and health professionals providing neurostimulation treatment.

The relevant provisions state:

5. The Ontario Neurotherapy College may designate a neurostimulation device as a Provincially Approved Device where satisfied that its supervised clinical use is consistent with acceptable standards of medical practice.

8(1). A licensed neurostimulation clinic shall make a Provincially Approved Device available to a patient where the treating physician certifies that:

(a) the patient suffers from a serious psychiatric or neurological condition;

(b) at least two conventional therapies have been unsuccessful or medically inappropriate; and

(c) use of the device is clinically appropriate.

8(2). Treatment under subsection

(1) remains subject to the informed consent of the patient.

9. A device shall not be disqualified from designation or use under this Act merely because the device has not received an approval, licence or listing from another Canadian governmental authority.

The Ontario Minister of Health explained when the TNCA was enacted that its purpose was:

“to regulate the practice of neurostimulation as a health service and to ensure that patients with serious conditions can access treatment under professional supervision.”

In 2025, the Ontario Neurotherapy College approved PulseArc.

The College reviewed two controlled studies, clinical data from approximately 7,000 supervised treatments and evidence from neurologists and psychiatrists.

No serious neurological injury had been reported from supervised PulseArc treatment.

Several researchers nevertheless cautioned that the long-term evidence remained incomplete.

NeuroVanta subsequently applied to have PulseArc placed on the federal Registry.

Federal reviewers accepted that there was no established pattern of serious injury associated with PulseArc.

They nevertheless concluded that the evidence did not yet establish its long-term therapeutic effectiveness to the standard required under s. 5 of the NNSA.

The Minister therefore refused to list PulseArc.

The federal assessment stated:

“The principal deficiency in the application is the absence of sufficient long-term controlled evidence demonstrating sustained therapeutic benefit. The current record does not establish that PulseArc presents a greater immediate neurological risk than comparable devices already used in clinical environments.”

As a result, s. 4 of the NNSA now makes it an offence for an Ontario clinic to provide PulseArc treatment even though PulseArc remains a Provincially Approved Device under the TNCA.

NeuroVanta stopped shipping new PulseArc units but continued supporting clinics that already owned them.

Federal inspectors warned NeuroVanta that technical assistance provided for continued treatment could amount to participation in a contravention of s. 4.

One of the affected patients is Anika Rousseau, a 38-year-old Ontario resident who has experienced severe treatment-resistant depression for several years.

Her psychiatrist, Dr. Martin Okafor, has tried multiple medications and two other recognized therapies.

Two treatments produced serious adverse effects and had to be discontinued.

Dr. Okafor concludes that PulseArc is the only remaining non-invasive treatment he presently considers medically reasonable for Anika.

He certifies that she satisfies all three requirements of s. 8(1) of the TNCA.

The Ontario clinic treating Anika owns a PulseArc unit.

Before enactment of the NNSA, she had completed four supervised treatments and reported significant improvement.

Her treatment was then suspended after the federal prohibition came into force.

Dr. Okafor states that interruption of treatment creates a significant risk of deterioration in Anika’s psychological condition.

He cannot say with certainty whether PulseArc will provide lasting improvement.

The clinic refuses to resume treatment because its medical director does not want its staff exposed to federal criminal liability.

Anika is prepared to provide informed consent and acknowledges the remaining scientific uncertainty.

The federal government responds that Parliament is not obliged to accept Ontario’s assessment of medical risk or efficacy and that allowing individual provincial exemptions would undermine national safety standards.

A second dispute concerns NeuroVanta’s communications with physicians.

NeuroVanta prepared an information package for psychiatrists summarizing peer-reviewed studies concerning PulseArc.

Among other things, it states:

“In two controlled studies, 47% of participating patients experienced remission at 12 weeks.”

It also states:

“No serious neurological adverse event has been identified in approximately 7,000 reported supervised treatments.”

NeuroVanta says both statements accurately reproduce the published scientific literature.

Because PulseArc is not federally listed, s. 7(1) prohibits NeuroVanta from distributing the information for the purpose of encouraging physicians to use PulseArc.

Federal officials have also told NeuroVanta that a planned webinar in which independent researchers would discuss the studies could constitute prohibited promotion if NeuroVanta sponsors the event.

Separately, NeuroVanta manufactures another device called NeuroCalm, which is federally listed.

The approved federal monograph for NeuroCalm states only:

“Clinical studies demonstrate a measurable therapeutic response in some patients.”

NeuroVanta wants to advertise a newly published study reporting a 61% response rate.

Federal officials advise that s. 7(2) prohibits that statement because it does not appear in substantially identical form in the approved product monograph, even if the study itself is methodologically sound.

NeuroVanta argues that Parliament is suppressing truthful scientific and commercial expression rather than merely prohibiting false or misleading advertising.

The federal government responds that medical-product promotion can influence vulnerable patients and prescribing practices and that requiring federally reviewed claims is an important element of the safety scheme.

A third issue concerns s. 9 of the NNSA.

A customer in Ontario recently filed a proposed civil action against another neurotechnology company after suffering an injury from a device used entirely within Ontario.

The claim relies exclusively on s. 9 and does not allege negligence.

NeuroVanta is concerned that the same provision could expose it to civil liability for economic or psychological losses arising from purely intraprovincial dealings.

Ontario has intervened in the litigation and argues that Parliament has created a federal private-law cause of action governing local transactions and civil liability, matters that ordinarily fall within provincial jurisdiction over property and civil rights.

The Attorney General of Canada responds that s. 9 is an enforcement mechanism integrated into the federal safety regime.

Meanwhile, the conflict between the NNSA and the TNCA has become immediate.

Ontario has advised licensed clinics that s. 8 of the TNCA remains in force and that a clinic failing to provide a Provincially Approved Device to an eligible patient may face provincial disciplinary consequences.

Federal officials have advised the same clinics that providing treatment with an unlisted device is an offence under s. 4 of the NNSA.

Ontario’s Attorney General maintains that provincial regulation of medical treatment and professional health services lies at the core of provincial authority over property and civil rights.

The Attorney General of Canada does not dispute Ontario’s general authority to regulate health services but argues that valid federal criminal legislation prevails where simultaneous obedience is impossible.

Ontario responds that the federal legislation is itself invalid because its true character is the detailed regulation of medical devices, clinical treatment, advertising and civil liability rather than the creation of a genuine criminal prohibition.

NeuroVanta and Anika have now retained your firm.

They want to challenge the federal legislation.

Ontario has indicated that it will support their division-of-powers arguments concerning ss. 4 and 9, although it will defend the constitutional validity of the TNCA.

The federal government intends to defend the NNSA in full.

No party alleges that the Charter does not apply to the federal legislation.

Do not address negligence law, product-liability law apart from s. 9, medical malpractice, administrative-law review of the Minister’s individual listing decision, or the constitutional validity of any professional disciplinary proceeding that has not yet occurred.

QUESTION

The senior partner at your firm asks you to prepare a brief but comprehensive memorandum advising NeuroVanta and Anika on the significant Canadian constitutional law issues arising from these events.

Your memorandum should assess the constitutional validity and operation of the relevant federal and provincial legislation, the Charter implications of the federal restrictions on treatment and communication, the strongest competing arguments available to the governments, and the remedies that may realistically follow from any constitutional violation.

Do not merely identify constitutional doctrines. Apply the governing constitutional provisions and assigned Canadian authorities closely to the facts.

100 MARKS